These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 16818367

  • 1. From plasmids to protection: a review of DNA vaccines against infectious diseases.
    Laddy DJ, Weiner DB.
    Int Rev Immunol; 2006; 25(3-4):99-123. PubMed ID: 16818367
    [Abstract] [Full Text] [Related]

  • 2. Human clinical trials of plasmid DNA vaccines.
    Liu MA, Ulmer JB.
    Adv Genet; 2005; 55():25-40. PubMed ID: 16291211
    [Abstract] [Full Text] [Related]

  • 3. DNA vaccines: successes and limitations in cancer and infectious disease.
    Lowe DB, Shearer MH, Kennedy RC.
    J Cell Biochem; 2006 May 15; 98(2):235-42. PubMed ID: 16440328
    [Abstract] [Full Text] [Related]

  • 4. Designing immune responses with genetic immunization and immunostimulatory DNA sequences.
    Thalhamer J, Leitner W, Hammerl P, Brtko J.
    Endocr Regul; 2001 Sep 15; 35(3):143-66. PubMed ID: 11674843
    [Abstract] [Full Text] [Related]

  • 5. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants.
    Calarota SA, Weiner DB.
    Immunol Rev; 2004 Jun 15; 199():84-99. PubMed ID: 15233728
    [Abstract] [Full Text] [Related]

  • 6. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses.
    Barouch DH, Letvin NL, Seder RA.
    Immunol Rev; 2004 Dec 15; 202():266-74. PubMed ID: 15546399
    [Abstract] [Full Text] [Related]

  • 7. DNA vaccines: an historical perspective and view to the future.
    Liu MA.
    Immunol Rev; 2011 Jan 15; 239(1):62-84. PubMed ID: 21198665
    [Abstract] [Full Text] [Related]

  • 8. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques.
    Chong SY, Egan MA, Kutzler MA, Megati S, Masood A, Roopchard V, Garcia-Hand D, Montefiori DC, Quiroz J, Rosati M, Schadeck EB, Boyer JD, Pavlakis GN, Weiner DB, Sidhu M, Eldridge JH, Israel ZR.
    Vaccine; 2007 Jun 21; 25(26):4967-82. PubMed ID: 17335943
    [Abstract] [Full Text] [Related]

  • 9. Rational design of gene-based vaccines.
    Barouch DH.
    J Pathol; 2006 Jan 21; 208(2):283-9. PubMed ID: 16362986
    [Abstract] [Full Text] [Related]

  • 10. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
    Rodríguez-Cortés A, Ojeda A, López-Fuertes L, Timón M, Altet L, Solano-Gallego L, Sánchez-Robert E, Francino O, Alberola J.
    Vaccine; 2007 Nov 14; 25(46):7962-71. PubMed ID: 17942199
    [Abstract] [Full Text] [Related]

  • 11. DNA vaccines for emerging infectious diseases: what if?
    Whalen RG.
    Emerg Infect Dis; 1996 Nov 14; 2(3):168-75. PubMed ID: 8903226
    [Abstract] [Full Text] [Related]

  • 12. [DNA vaccination].
    Moradpour D, Blum HE.
    Praxis (Bern 1994); 2000 Oct 26; 89(43):1745-8. PubMed ID: 11103619
    [Abstract] [Full Text] [Related]

  • 13. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
    Jiang W, Ren L, Jin N.
    J Virol Methods; 2007 Dec 26; 146(1-2):266-73. PubMed ID: 17868910
    [Abstract] [Full Text] [Related]

  • 14. DNA vaccines.
    Donnelly JJ, Ulmer JB, Liu MA.
    Dev Biol Stand; 1998 Dec 26; 95():43-53. PubMed ID: 9855413
    [Abstract] [Full Text] [Related]

  • 15. [DNA--the future in vaccine technology?].
    Kjeken R, Bogen B, Mathiesen I.
    Tidsskr Nor Laegeforen; 2006 Nov 16; 126(22):2964-8. PubMed ID: 17117196
    [Abstract] [Full Text] [Related]

  • 16. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant.
    Zhang Y, Jiang W, Fan Y, Wen J, Hao W, Qian M.
    J Virol Methods; 2008 Nov 16; 153(2):142-8. PubMed ID: 18722475
    [Abstract] [Full Text] [Related]

  • 17. Chemical adjuvants for plasmid DNA vaccines.
    Greenland JR, Letvin NL.
    Vaccine; 2007 May 10; 25(19):3731-41. PubMed ID: 17350735
    [Abstract] [Full Text] [Related]

  • 18. Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains.
    Ferrone CR, Perales MA, Goldberg SM, Somberg CJ, Hirschhorn-Cymerman D, Gregor PD, Turk MJ, Ramirez-Montagut T, Gold JS, Houghton AN, Wolchok JD.
    Clin Cancer Res; 2006 Sep 15; 12(18):5511-9. PubMed ID: 17000687
    [Abstract] [Full Text] [Related]

  • 19. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
    Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M, Miles S, Liu X, Obrocea M, Qiu Z, Bot A.
    J Immunother; 2008 Sep 15; 31(2):215-23. PubMed ID: 18481391
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
    Rollman E, Mathy N, Bråve A, Boberg A, Kjerrström A, van Wely C, Engström G, Johansson S, Aperia K, Eriksson LE, Benthin R, Ertl P, Heeney J, Hinkula J, Voss G, Wahren B.
    Vaccine; 2007 Mar 01; 25(11):2145-54. PubMed ID: 17254672
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.